A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes

Inclusion Criteria: * Participants with type 2 diabetes (T2D) ≥ 6 months according to the World Health Organization (WHO) classification. * Treated with stable doses of a single OAM for at least 8 weeks prior to screening; the dose must be more than or equal to minimum maintenance dose. * Have the following HbA1c result at screening. * Participants taking DPP-4i: ≥7.5% and ≤9.5%, * Participants taking another OAM: ≥8.0% and ≤10.0% * Stable body weight for at least 8 weeks prior to screening or not changed by more than 5 % in the past 8 weeks * Have a body mass index (BMI) ≥18.5 kilogram/square meter (kg/m²) and \<35 kg/m² at Day 1. Exclusion Criteria: * Have type 1 diabetes (T1D) * Have a history of ≥1 episode of ketoacidosis or hyperosmolar state/coma * Have had any myocardial infarction (MI), heart failure or cerebrovascular accident (stroke) * Have a known clinically significant gastric empty abnormality * Have acute or chronic hepatitis * Have had chronic or acute pancreatitis * Have any self or family history of type 2A or type 2B multiple endocrine neoplasia in the absence of known C-cell hyperplasia * Have any self or family history of medullary C-cell hyperplasia, focal hyperplasia, or carcinoma (including sporadic, familial, or part of Multiple endocrine neoplasia (MEN) 2A or 2B syndrome) * Have evidence of significant, active autoimmune abnormality * Have evidence of significant, uncontrolled endocrine abnormality * Have active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer) for less than 5 years * Have any hematologic condition that may interfere with HbA1c measurement